The transactions were executed under a Rule 10b5-1 trading plan, which allows company insiders to set a predetermined plan for selling stock to avoid concerns about insider trading. Following these transactions, Forbes holds a total of 1,383,441 MeiraGTx shares directly owned.
The transactions were executed under a Rule 10b5-1 trading plan, which allows company insiders to set a predetermined plan for selling stock to avoid concerns about insider trading. Following these transactions, Forbes holds a total of 1,383,441 MeiraGTx shares directly owned.
The transactions were executed under a Rule 10b5-1 trading plan, which allows company insiders to set a predetermined plan for selling stock to avoid concerns about insider trading. Following these transactions, Forbes holds a total of 1,383,441 MeiraGTx shares directly owned.
In other recent news, MeiraGTx Holdings (NASDAQ: ) has achieved significant milestones in its clinical trials and financial development. The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company’s AAV2-hAQP1 gene therapy candidate for the treatment of radiation-induced xerostomia. This regulatory advance reflects the therapy’s potential as a one-time treatment for a condition that affects a large number of head and neck cancer patients.
MeiraGTx also reported positive results from its MGT-GAD-025 clinical trial, aimed at treating Parkinson’s disease. The trial showed significant improvements in patients with idiopathic Parkinson’s disease. The company plans to work with regulators in the US, Europe and Japan to launch a Phase 3 study.
Financial analysts have shown confidence in MeiraGTx’s prospects. Piper Sandler maintained its Overweight rating on the company’s stock, citing potential near-term catalysts and an expected $285 million milestone from its partnership with Johnson & Johnson (NYSE: ). Similarly, RBC Capital maintained an Outperform rating, adjusting its price target for the company.
Additionally, MeiraGTx announced a public offering of 12.5 million common shares at $4 each, with the goal of generating $50 million for research and development and clinical trial expenses. Chardan Capital Markets initiated coverage on MeiraGTx with a Buy rating, expressing confidence in the gene therapy development company. These are among recent events that highlight MeiraGTx’s ongoing financial and research activities.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
